EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimized CRISPR-Cas9 system for efficient engineering of ecDNA in cancer cells

Yohei Sugimoto iD, Takeru Kachi, Yu Watanabe, Mei Kubokawa, Koichi Ogami iD, Masaki Kawamata, Seiko Yoshino, Hiroshi I Suzuki iD

Nucleic Acids Research · 14.01.2026 · 54 (2)

DOI: 10.1093/nar/gkag005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 14.01.2026. Verfasst von Yohei Sugimoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Extrachromosomal DNA, Gene Editing, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extrachromosomal DNA (ecDNA) amplification represents an emerging mechanism underlying oncogene amplification, tumor heterogeneity, and drug resistance in cancer. However, the biology of ecDNA remains poorly understood because tools to engineer ecDNAs and precisely monitor their dynamics are limited. In particular, genome engineering strategies have not been established for ecDNA, which exists in tens to hundreds of copies within a single cell. Here, we report a systematic validation of ecDNA editing using standard CRISPR-Cas9 system and optimized CRISPR-Cas9 system with safeguard single-guide RNAs (sgRNAs), in which the addition of cytosine extensions finely reduces excessive Cas9 activity. The conventional CRISPR-Cas9 system induced severe cytotoxicity and markedly reduced ecDNA copy number, together with frequent micronucleus formation. Knock-in efficiency was remarkably low, highlighting an intrinsic difficulty in editing ecDNA. In contrast, the safeguard sgRNA strategy not only alleviated cytotoxicity and ecDNA loss in a cytosine-length–dependent manner but also enabled efficient knock-in into multiple ecDNA per cell. Computational simulations suggested that the degree and temporal patterns of multiple DNA cleavage events shape cell death, micronucleus formation, and rapid expansion of knock-in ecDNA. Collectively, optimization of Cas9 activity using safeguard sgRNAs enables efficient and nondisruptive ecDNA engineering, providing a powerful tool to study ecDNA biology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsExtrachromosomal DNAGene EditingNeoplasmsHumansRNA, Guide, CRISPR-Cas SystemsCell Line, TumorGene Knock-In Techniques

Substanzen

Extrachromosomal DNARNA, Guide, CRISPR-Cas Systems

Autor:innen und Institutionen

  • Division of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  • Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  • Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  • Division of Organogenesis and Regeneration, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan.
  • Institute for Glyco-core Research, Nagoya University, Nagoya 464-8601, Japan.
  • Center for One Medicine Innovative Translational Research, Nagoya University, Nagoya 464-8601, Japan.

ORCID-Profile: Yohei Sugimoto, Koichi Ogami, Hiroshi I Suzuki

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Takeda Science Foundation
  • oray Science Foundation
  • Inamori Research Institute for Science
  • JSPS
  • Nagoya University
  • JST-SPRING

Zitieren

APA

Sugimoto, Y., Kachi, T., Watanabe, Y., Kubokawa, M., Ogami, K., Kawamata, M., Yoshino, S., & Suzuki, H. I. (2026). Optimized CRISPR-Cas9 system for efficient engineering of ecDNA in cancer cells. Nucleic Acids Research, 54(2). https://doi.org/10.1093/nar/gkag005

Vancouver

Sugimoto Y, Kachi T, Watanabe Y, Kubokawa M, Ogami K, Kawamata M, et al. Optimized CRISPR-Cas9 system for efficient engineering of ecDNA in cancer cells. Nucleic Acids Research. 2026;54(2). doi:10.1093/nar/gkag005

BibTeX
@article{Sugimoto2026,
  author = {Sugimoto, Yohei and Kachi, Takeru and Watanabe, Yu and Kubokawa, Mei and Ogami, Koichi and Kawamata, Masaki and Yoshino, Seiko and Suzuki, Hiroshi I},
  title = {Optimized CRISPR-Cas9 system for efficient engineering of ecDNA in cancer cells},
  journal = {Nucleic Acids Research},
  year = {2026},
  volume = {54},
  number = {2},
  doi = {10.1093/nar/gkag005}
}
Kostenlos starten →